RESEARCHER PROFILE

Nancy L. Bartlett

← Back to Washington University in St. Louis

N

Washington University in St. Louis

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchViral-associated cancers and disordersCAR-T cell therapy researchCutaneous lymphoproliferative disorders research

Nancy L. Bartlett works in Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Viral-associated cancers and disorders, CAR-T cell therapy research, Cutaneous lymphoproliferative disorders research. Recorded institutional associations include Barnes-Jewish Hospital, Washington University in St. Louis, Alvin J. Siteman Cancer Center.

947Publications
49,237Citations
98H-index

ORCID

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    2017 · 5,991 citations

  2. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

    2018 · 2,276 citations

  3. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma

    2018 · 2,231 citations

  4. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

    2015 · 1,583 citations

  5. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

    2012 · 1,529 citations

  6. Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

    2010 · 1,368 citations

  7. Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

    2002 · 1,170 citations

  8. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

    2018 · 1,126 citations

  9. Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

    2012 · 997 citations

  10. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

    2018 · 962 citations

  11. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

    2017 · 789 citations

  12. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    2018 · 739 citations

  13. Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

    2011 · 647 citations

  14. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

    2017 · 620 citations

  15. Barriers to Clinical Trial Participation by Older Women With Breast Cancer

    2003 · 465 citations

  16. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

    2022 · 461 citations

  17. Non-Hodgkin's Lymphomas

    2011 · 454 citations

  18. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

    2019 · 434 citations

  19. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

    2015 · 415 citations

  20. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

    2018 · 371 citations

  21. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin

    2014 · 352 citations

  22. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

    2022 · 347 citations

  23. Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin's Disease: Mature Results of a Prospective Clinical Trial

    2002 · 326 citations

  24. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

    2017 · 322 citations

  25. Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)

    2012 · 308 citations

← Return to the university profile